C-Q13OLeucadia Therapeutics
outpatient treatment, diagnostics, CT scan
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-Q13O
C-Q13OC-Q13Ooutpatient treatment, diagnostics, CT scan
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Leucadia Therapeutics outpatient treatment, diagnostics, CT scan
Leucadia Therapeutics is working to end Alzheimer's disease with Arethusta, described as a first-in-class outpatient treatment. Its first mission is to test Arethusta by reversing mild cognitive impairment associated with Alzheimer's disease, with later intent to prevent and cure Alzheimer's itself. The company is also running Project Cribrose, a 2,000-person clinical study to assess Alzheimer's disease risk and refine proprietary diagnostic tools.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Leucadia Therapeutics — Far from goals · Bottom quartile. Derived deterministically from 3 extracted project(s). Most-advanced status: undisclosed. Band: far. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic